SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech's $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines.


10


Reuters

Latest News

CNN: Look out Red Bull. Monster is flying

BBC: Child refugees at Calais aiming to leave France for UK

BBC: Bid to safeguard Traditional Welsh Caerphilly cheese name

ABC: Olympic star Aly Raisman shows up in court to face abuser Larry Nassar

ABC: Meghan Markle has wedding dress fitting at Kensington Palace: Source

Daily Mail: Nick Kyrgios gushes over Will Smith at Australian Open

Daily Mail: Rocket League Championship Series season five will...

Daily Mail: BC-SOC--English Standings

Daily Mail: Prep school says lawsuit settled in sex assault case

CNBC: Stocks open higher but worries of government shutdown loom

CNBC: Rising mortgage rates could mean even fewer homes for sale this spring

CTV News: 'Jersey Shore' reality star expected to plead to tax charges

Reuters: North Korea cancels visit to prepare for Olympic performance in South Korea - Yonhap

Times of Israel: 650 works from NY Jewish Museum’s private stockpile on show in massive exhibit

WashingtonPost: Brexit costs Britain data center for Europe’s satnav system

WashingtonPost: It's not just Ballou: Schools across D.C. are graduating students who were chronically absent

FOX: Man accused of threatening Georgia mosque pleads not guilty

FOX: Peace be with you, but no touching: Flu season altering Mass

FOX: Construction worker impaled by two iron rods, one inches from heart, miraculously survives

FOX: FISA surveillance program: What is it and why is it so controversial?

FOX: Fusion GPS's ties to Clinton campaign, Russia investigation: What to know

CNN: Horse breeders struggling as Cape Town drought bites

BBC: Irish message on Brexit and EU's future